# Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

> **NCT05616221** · PHASE2 · COMPLETED · sponsor: **Armata Pharmaceuticals, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Non-cystic Fibrosis Bronchiectasis
- Pseudomonas Aeruginosa
- Lung Infection

## Interventions

- **BIOLOGICAL:** AP-PA02
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05616221
- **Lead sponsor:** Armata Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-10
- **Primary completion:** 2024-07-17
- **Final completion:** 2024-08-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05616221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05616221, "Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05616221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*